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Introduction {#sec005}
============

In 2016, tuberculosis (TB) affected 10.4 million people and claimed 1.7 million deaths worldwide \[[@pone.0210479.ref001]\]. Treatment outcomes for TB are unsatisfactory, as therapy is prolonged, complex, and often results in poor compliance \[[@pone.0210479.ref002]\]. Researchers have been searching for adjunctive therapies to use in combination with standard anti-TB therapy. Promising agents that are currently available include lipid-lowering agents (LLAs) \[[@pone.0210479.ref003]\]. Recent in vitro and animal studies showed that statins, alone or in combination with first-line anti-TB therapy, may reduce bacterial burden and enhance bactericidal activity \[[@pone.0210479.ref004]\]. Although the mechanism remains to be established, reduced levels of cholesterol in the cell membrane may reverse the arrest of phagosomal maturation induced by *Mycobacterium tuberculosis* \[[@pone.0210479.ref005]\]. Another type of LLA, fibrate, has been shown to inhibit intracellular growth of TB by inhibiting enoyl reductase \[[@pone.0210479.ref006]\] and inflammation caused by *Mycobacterium smegmatis* through a PPARα-independent pathway \[[@pone.0210479.ref007]\]. Clinical observation revealed the statin therapy was associated with a decreased risk of active TB \[[@pone.0210479.ref008]\]; however, no previous human study has been conducted in tuberculosis-infected patients. Using the Taiwan National Health Insurance Research Database (NHIRD) from Jan. 1, 2003 to Dec. 31, 2010, the current population-based cohort study sought to examine the association between use of LLAs and outcomes of patients with pulmonary TB receiving anti-TB treatment.

Material and methods {#sec006}
====================

The NHIRD contains demographic data, diagnoses according to the International Classification of Disease ninth revision (ICD-9-CM), procedures, and medications \[[@pone.0210479.ref009]\]. The Taiwan's NHI program covers 99% of the population in 2004, and the coverage provides outpatient service and inpatient care. The Taiwanese Centers for Disease Control (TCDC) stipulate mandatory registry of newly diagnosed TB cases and monitoring of treatment. To encourage compliance with TCDC guidelines, physicians were rewarded with extra reimbursement through NHIRD if patients were diagnosed and treated according to TCDC guidelines. The reimbursement of claims related to a diagnosis of TB requires the positivity of microbiological tests or presence of pathological evidence typical of TB. This retrospective study included adult patients with new diagnoses of pulmonary TB (011.x) and double confirmation from NHIRD during the period from 2003--2010, the prescription of at least 2 anti-TB drugs (e.g., isoniazid, ethambutol, rifampin, pyrazinamide) for 2 months. Patients with age \<20 years, a concomitant diagnosis of extra-pulmonary TB (010.x, 012.x--018.x), or antecedent TB were excluded. Patients were divided in two cohorts: in the LLA cohort, patients received fibrates or statins during the course of treatment for TB; members of the propensity-matched comparison cohort did not receive LLA. Each patient in the former group was matched with 4 patients in the comparison cohort with propensity score (±0.1SD) in terms of age (±5 years), sex, the year and month of index visit, monthly income, urbanization level, and comorbidities \[[@pone.0210479.ref010]\]. In order to ensure appropriate assessment of comorbid conditions as defined by ICD-9-CM codes, all patients included in the study were available for at least 3 years of follow-up \[[@pone.0210479.ref009]\]. The comorbidities included hypertension (ICD-9-CM: 401 and 405), diabetes mellitus (ICD-9-CM: 250), cerebrovascular disease (ICD-9-CM: 430--438), coronary artery disease (ICD-9-CM: 414), heart failure (ICD-9-CM: 428), myocardial infarction (ICD-9-CM:410), arrhythmia (ICD-9-CM: 427), dyslipidemia (ICD-9-CM: 272), chronic kidney disease (ICD-9-CM: 585), and chronic liver disease (ICD-9-CM:571). The primary outcome was the incidence of treatment completion at 9, 12, and 24 months after anti-TB drugs were administered. Some patients used stain and fibrate sometimes. Treatment completion was confirmed by the reimbursement to physicians from the NHIRD for compliance with TCDC policy. All subjects were followed until death, loss to follow-up, completion of treatment, or two years after initiation of anti-TB drugs.

Baseline demographic characteristics between the patients with and without LLA user were compared by use of the Pearson χ^2^ test for categorical variables and the independent *t* test for parametric continuous variables. The incidence rates of tuberculosis treatment completion at 9, 12, and 24 months and control cohort were calculated from Poisson distribution. We used Cox regression models to calculate crude and adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) of tuberculosis treatment completion at 9, 12, and 24 months and control cohort.\[[@pone.0210479.ref011]\] The SQL Server 2012 (Microsoft Corp, Redmond, WA) was used for data linkage, processing, and sampling. Calculation of Propensity scores was performed with SAS version 9.3 (SAS Institute, Cary, NC). Other statistical analyses were conducted with STATA statistical software (version 12.0; StataCorp, College Station, TX). A P value \<0.05 was considered statistically significant.

The study was reviewed and approved by the institutional review board of National Health Research Institute \[EC1041007-E\]).

Results {#sec007}
=======

A total of 1452 adult patients newly diagnosed with pulmonary TB were identified; 5808 matched patients were included in the comparison cohort ([Fig 1](#pone.0210479.g001){ref-type="fig"}). Mean age in the LLA cohort was 65 years. The majority of LLA patients were male (69.9%), and had ≥ 4 comorbidities (64.7%). Dyslipidemia (83.5%) was the most common comorbid disease, followed by hypertension (78.5%) and diabetes mellitus (72.3%). There was higher prevalence rates of myocardial infarction (8.6% vs. 7.0%) in the patients with LLA cohort compared to those without LLA. ([Table 1](#pone.0210479.t001){ref-type="table"})

![Overall framework of the research design and sampling strategy.\
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###### Characteristics of patients with newly diagnosed pulmonary tuberculosis.
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  --------------------------------------------------------------------------------------------------------------------------------
  Characteristics                                                              Lipid lowing agent user   Matched control   *P*\
                                                                                                                           value
  ---------------------------------------------------------------------------- ------------------------- ----------------- -------
  **Patient No.**                                                              1452                      5808              

  **Age, mean (SD), years**                                                    65.1 (12.5)               65.3 (12.4)       0.581

  **Male sex**                                                                 1,016 (69.9%)             4,064 (69.9%)     1.000

  **Monthly income**                                                                                                       0.933

  **     Dependent**                                                           448 (30.8%)               1,837 (31.6%)     

  **     0--19 100 NT dollars**                                                334 (23%)                 1,306 (22.4%)     

  **     19 100--42 000 NT dollars**                                           600 (41.3%)               2,395 (41.2%)     

  **     \> 42 000 NT dollars**                                                70 (4.8%)                 270 (4.6%)        

  **Urbanization**[^a^](#t001fn002){ref-type="table-fn"}                                                                   0.962

  **     Level 1**                                                             747 (51.4%)               3,009 (51.8%)     

  **     Level 2**                                                             578 (39.8%)               2,273 (39.1%)     

  **     Level 3**                                                             110 (7.5%)                455 (7.8%)        

  **     Level 4**                                                             17 (1.1%)                 71 (1.2%)         

  **Charlson comorbidity index score**[^b^](#t001fn003){ref-type="table-fn"}                                               0.072

  **    0**                                                                    26 (1.7%)                 55 (0.9%)         

  **     1**                                                                   109 (7.5%)                404 (6.9%)        

  **     2**                                                                   177 (12.1%)               698 (12%)         

  **     3**                                                                   200 (13.7%)               849 (14.6%)       

  **     ≥ 4**                                                                 940 (64.7%)               3,802 (65.4%)     

  **Using lipid lowering agents**                                                                                          

  **     Statins**                                                             1208                      \-                

  **     Fibrates**                                                            295                       \-                

  **Comorbid disease**                                                                                                     

  **     Hypertension**                                                        1,141 (78.5%)             4,582 (78.8%)     0.796

  **     Diabetes mellitus**                                                   1,050 (72.3%)             4,299 (74%)       0.187

  **     Cerebrovascular disease**                                             527 (36.2%)               2,062 (35.5%)     0.573

  **     Coronary artery disease**                                             765 (52.6%)               2,998 (51.6%)     0.467

  **     Heart failure**                                                       297 (20.4%)               1,092 (18.8%)     0.152

  **     Myocardial infarction**                                               126 (8.6%)                411 (7.0%)        0.037

  **     Arrhythmia**                                                          525 (36.1%)               2,108 (36.2%)     0.922

  **     Dyslipidemia**                                                        1,213 (83.5%)             4,875 (83.9%)     0.714

  **     Chronic kidney disease**                                              398 (27.4%)               1,602 (27.5%)     0.895

  **     Chronic liver disease**                                               557 (38.3%)               2,337 (40.2%)     0.191

  **Propensity score (SD)**                                                    0.10 (0.06)               0.10 (0.06)       0.978
  --------------------------------------------------------------------------------------------------------------------------------

SD: standard deviation; NT\$: new Taiwan dollars.

^a^Urbanization levels in Taiwan are divided into four strata according to the Taiwan National Health Research Institute publications. Level 1 designates the most urbanized areas, and level 4 designates the least urbanized areas.

^b^Charlson Comorbidity Index (CCI) score is used to determine overall systemic health. With each increased level of CCI score, there are stepwise increases in the cumulative mortality.

In the LLA cohort, 1258 patients received statins, and 295 received fibrates. Compared with patients who did not take LLA, patients who took LLAs showed no increase in the rate of treatment completion ([Table 2](#pone.0210479.t002){ref-type="table"}). The incidence of treatment completion was similar at 9, 12, and 24 months (incidence 1.16 vs. 1.11, adjusted hazard ratio \[aHR\] 1.04, 95% confidence interval \[CI\] 0.96--1.12 at 9 months; incidence 1.06 vs. 1.02, aHR 1.04, 95% CI 0.96--1.11 at 12 months; and incidence 0.71 vs. 0.69, aHR 1.03, 95% CI 0.97--1.11 at 24 months).

10.1371/journal.pone.0210479.t002

###### Incidence and hazard ratio of among tuberculosis patients.
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                       Propensity Score--Matched                                                                               
  -------------------- --------------------------- ------ ------ ------ ------------------- -------------- ------------------- -------
  *9 months*                                                                                                                   
  **Control cohort**   2116                        3361   2931   1.15   As Reference        As Reference                       
  **Using LLA**        555                         865    746    1.16   1.04 (0.96--1.12)   0.319          1.04 (0.96--1.12)   0.309
  **   Statin**        459                         721    621    1.16   1.04 (0.95--1.12)   0.398          1.04 (0.96--1.12)   0.384
  **   Fibrate**       111                         164    143    1.15   1.04 (0.88--1.24)   0.616          1.04 (0.88--1.24)   0.648
  *12 months*                                                                                                                  
  **Control cohort**   1825                        3508   3430   1.02   As Reference        As Reference                       
  **Using LLA**        479                         930    877    1.06   1.04 (0.96--1.11)   0.335          1.04 (0.96--1.11)   0.324
  **   Statin**        398                         773    730    1.06   1.03 (0.95--1.12)   0.424          1.03 (0.96--1.12)   0.409
  **   Fibrate**       94                          178    169    1.06   1.04 (0.89--1.23)   0.603          1.04 (0.88--1.23)   0.640
  *24 months*                                                                                                                  
  **Control cohort**   1622                        3565   5140   0.69   As Reference        As Reference                       
  **Using LLA**        440                         943    1332   0.71   1.03 (0.96--1.11)   0.370          1.03 (0.97--1.11)   0.359
  **   Statin**        365                         784    1108   0.71   1.03 (0.95--1.12)   0.463          1.03 (0.95--1.12)   0.446
  **   Fibrate**       87                          181    258    0.70   1.05 (0.89--1.23)   0.572          1.04 (0.89--1.23)   0.610

HR: hazards ratio; CI: confidence interval; LLAs: lipid-lowering agents.

\* Per person-years.

^a^ Adjusted for propensity score.

Discussion {#sec008}
==========

The protective effect of statins, as either monotherapy or adjunctive therapy, against TB has been demonstrated \[[@pone.0210479.ref012]\]. Despite the lack of a direct anti-mycobacterial effect, statins reduce bacterial burden by reducing cholesterol accumulation within *Mycobacterium tuberculosis* and enhancing autophagy and phagosomal maturation \[[@pone.0210479.ref005]\]. These effects may be mediated by the anti-inflammatory response and immunomodulatory effects \[[@pone.0210479.ref012]\]. Clinical studies have confirmed that statin treatment is associated with a lower incidence of active TB \[[@pone.0210479.ref003], [@pone.0210479.ref008]\]. Recent studies have demonstrated their use as an adjunct in combination with standard therapy. Animal experiments showed statins enhance the bactericidal effect of standard therapy \[[@pone.0210479.ref004]\] and shorten the duration required to sterilize TB \[[@pone.0210479.ref013]\]. However, the results of our study failed to confirm the role of statins as adjunctive therapy to standard anti-TB treatment. Prolonged first-line treatment with anti-TB drugs is often successful in treating human patients, which may mask the adjunctive effect of statins. A mouse study also showed that after 4.5 months of anti-TB therapy, simvastatin provided no additional benefit when combined with standard therapy \[[@pone.0210479.ref013]\]. However, when treatment duration was decreased to 2.5 months, combination of simvastatin with standard therapy decreased the relapse rate of TB, compared to standard therapy alone. A prospective study comparing a standard course of anti-TB drugs with a short course of TB drugs in combination with LLAs may be warranted.

The strength of our study included propensity score-matching for multiple comorbid diseases. Nonetheless, our retrospective study has some limitations. First, this study was limited by the small number of patients who took fibrates during pulmonary TB infection. Second, treatment course may have been prolonged because of bacterial resistance or side effects of drug treatment. However, multidrug resistant strains of TB represented only 1.2% of new-onset TB cases in Taiwan \[[@pone.0210479.ref014]\]. Third, the beneficial effect of LLAs may require chronic use (\>90 days) \[[@pone.0210479.ref008]\]. The duration of statin use may have affected protection against TB \[[@pone.0210479.ref008], [@pone.0210479.ref015]\]. We did not systematically study accumulated dose in this study.

In the era of end TB strategy, we need new therapy or adjunctive therapy to shorten TB treatment. It is important to find therapeutic agents with which rate of treatment completion for TB infection can be enhanced in public health. We have yet to find the beneficial effects of statin with current anti-TB therapy, a prospective clinical trial is needed to show it in future.

Conclusion {#sec009}
==========

In conclusion, the results presented above do not support an adjunctive effect of LLAs in combination with standard anti-TB treatment. Further clinical trials are needed to investigate the adjunctive effect of statin and fibrate in the treatment of TB.
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